IMMUNIC, INC. — Director's Dealing 2024

Mar 6, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2024-03-04

Reporting Person: Vitt Daniel (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-04	Stock Option	$13.2900	D	65000	Disposed	2029-08-01	Common Stock (65000)	Direct
2024-03-04	Stock Option	$12.3000	D	80000	Disposed	2030-07-02	Common Stock (80000)	Direct
2024-03-04	Stock Option	$15.7200	D	115000	Disposed	2031-03-01	Common Stock (115000)	Direct
2024-03-04	Stock Option	$10.7300	D	215000	Disposed	2032-01-03	Common Stock (215000)	Direct
2024-03-04	Stock Option	$3.4000	D	10000	Disposed	2032-06-15	Common Stock (10000)	Direct
2024-03-04	Stock Option	$1.72	A	485000	Acquired		Common Stock (485000)	Direct

Footnotes

F1: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.